ArticleSensors (Basel, Switzerland)2009
From lateral flow devices to a novel nano-color microfluidic assay.
Article in Sensors (Basel, Switzerland), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Anything You Can Do, I Can Do Better: Can Aptamers Replace Antibodies in Clinical Diagnostic Applications?Molecules (Basel, Switzerland) · 2019Review
- Diagnostic tools for tackling febrile illness and enhancing patient management.Microelectronic engineering · 2018Article
- Investigation of Reagent Delivery Formats in a Multivalent Malaria Sandwich Immunoassay and Implications for Assay Performance.Analytical chemistry · 2016Article
- Point of Care Technologies for HIV.AIDS research and treatment · 2014Review
- Editorial: nanotechnological advances in biosensors.Sensors (Basel, Switzerland) · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improving the performance of traditional diagnostic lateral flow assays combined with new manufacturing technologies is a primary goal in the research and development plans of diagnostic companies. Taking into consideration the components of lateral flow diagnostic test kits; innovation can include modification of labels, materials and device design. In recent years, Resonance-Enhanced Absorption (REA) of metal nano-particles has shown excellent applicability in bio-sensing for the detection of a variety of bio-molecular binding interactions. In a novel approach, we have now integrated REA-assays in a diagnostic microfluidic setup thus resolving the bottleneck of long incubation times inherent in previously existing REA-assays and simultaneously integrated automated fabrication techniques for diagnostics manufacture. Due to the roller-coating based technology and chemical resistance, we used PET-co-polyester as a substrate and a CO(2) laser ablation system as a fast, highly precise and contactless alternative to classical micro-milling. It was possible to detect biological binding within three minutes - visible to the eye as colored text readout within the REA-fluidic device. A two-minute in-situ silver enhancement was able to enhance the resonant color additionally, if required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.